Endostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis
Abstract Background We aimed to clarify the benefits of the addition of rh‐endostatin into concurrent chemoradiotherapy (CCRT) versus CCRT alone for locally advanced non‐small cell lung cancer (NSCLC) by a meta‐analysis. Methods PubMed, Embase, Cochrane Central Register of Controlled Trials, Wanfang...
Main Authors: | Meng Yuan, Yirui Zhai, Yu Men, Jianyang Wang, Lei Deng, Wenqing Wang, Yongxing Bao, Xu Yang, Shuang Sun, Zeliang Ma, Yunsong Liu, Jun Wang, Hui Zhu, Zhouguang Hui |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-12-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.14188 |
Similar Items
-
Efficacy of concurrent chemoradiotherapy plus Endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study
by: Yuanxiu Yin, et al.
Published: (2022-07-01) -
Effectiveness and safety of Endostar combined with chemotherapy in treating advanced NSCLC patients with different ages
by: Wei Jiang, et al.
Published: (2023-03-01) -
Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy
by: Kuifei Chen, et al.
Published: (2024-02-01) -
Comparison of Endostar continuous versus intermittent intravenous infusion in combination with first‐line chemotherapy in patients with advanced non‐small cell lung cancer
by: Yuan Cheng, et al.
Published: (2019-07-01) -
The Efficacy and Safety of Continuous Intravenous Endostar Treatment Combined With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Squamous Cell Carcinoma: A Randomized Controlled Trial
by: Hang Shu, et al.
Published: (2021-08-01)